Compare Crispr Therapeutics AG (CRSP) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Roundhill NVDA WeeklyPay ETF — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Roundhill NVDA WeeklyPay ETF trades at $38.32. Which is the better fit depends on your goals.
| CRSP | NVDW | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $76.78 | $52.59 |
52-Week Low | $44.34 | $31.88 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
NVDW trades at $38.58, up 3.35% today with a bullish technical signal supported by moving averages. The stock shows strong momentum with key indicators suggesting mild overbought conditions. Recent dividend activity indicates consistent shareholder returns, though financial ratios remain undisclosed pending updated filings.
Outlook remains positive given technical strength and dividend consistency, but limited fundamental data requires caution. Key risks include dependency on underlying NVDA performance and payout volatility. Investors should await comprehensive financial disclosures for full valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
